Genetically Modified MSCs for Targeted Regeneration: Balancing Efficacy, Biosafety, and GMP Standardization

Area of Science:

• Cellular and Molecular Medicine
• Biotechnology
• Regenerative Medicine

Background:

• Mesenchymal stromal cells (MSCs) are promising for regenerative medicine and gene delivery due to inherent therapeutic properties.
• Challenges like donor variability, inconsistent biodistribution, and engineering risks hinder clinical translation.
• Current MSC therapies often lack molecular definition, impacting reproducibility and safety.

Purpose of the Study:

• To critically evaluate genetically modified MSCs as defined medicinal products.
• To compare different genetic engineering strategies for MSCs, including lentiviral transduction and genome editing.
• To review advancements in manufacturing, quality control, and design strategies for consistent MSC-based therapies.

Main Methods:

• Comparative analysis of self-inactivating lentiviral (SIN-LV) transduction and targeted genome editing techniques.
• Integration of preclinical and clinical data with Good Manufacturing Practice (GMP)-compatible processes.
• Evaluation of strategies like safe-harbor integration and hypoimmunogenic designs (B2M/CIITA).

Main Results:

• SIN-LV offers efficient, durable expression but has limited clinical data.
• Genome editing allows locus and copy number control but faces efficiency and safety concerns.
• Safe-harbor and hypoimmunogenic designs can mitigate batch and donor variability.

Conclusions:

• Developments support a shift from empirical MSC preparations to molecularly defined cellular medicines.
• Precise control over genotype, expression, potency, and safety is crucial for advanced MSC therapies.
• Standardized manufacturing and rigorous quality control are essential for clinical success.